5-苯基-2-噻吩基异氰酸酯 | 321309-34-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-苯基-2-噻吩基异氰酸酯
• 中文别名: 5-苯基-2-噻吩基异氰酸脂
• 英文名称: 5-phenyl-thien-2-yl isocyanate
• 英文别名: 5-phenyl-2-thienyl isocyanate；5-Phenyl-2-thienylisocyanate；2-isocyanato-5-phenylthiophene
• CAS: 321309-34-6
• 化学式: C₁₁H₇NOS
• mdl: MFCD02681998
• 分子量: 201.249
• InChiKey: HEDGSHFNFRGBDX-UHFFFAOYSA-N

物化性质

• 沸点：
  327.7±30.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  UN 2206

SDS

Name:	5-Phenyl-2-thienyl isocyanate Material Safety Data Sheet
Synonym:
CAS:	321309-34-6

Section 1 - Chemical Product MSDS Name:5-Phenyl-2-thienyl isocyanate Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
321309-34-6	5-Phenyl-2-thienyl isocyanate		unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 321309-34-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 105 - 108 deg C @0.05mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H7NOS
Molecular Weight: 201

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 321309-34-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Phenyl-2-thienyl isocyanate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 321309-34-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 321309-34-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 321309-34-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  9a-(3-aminopropyl)-9-deoxo-9a-aza-9a-homoerythromycin A 、 5-苯基-2-噻吩基异氰酸酯 以 二氯甲烷 为溶剂， 反应 48.0h， 生成
  参考文献：
  名称：

  一种自动化的聚合物辅助策略，可制备15元氮杂内酯的尿素和硫脲衍生物，作为潜在的抗疟疾化学疗法

  摘要：

  合成了一系列15元氮杂内酰胺脲和硫脲衍生物，并评估了它们对恶性疟原虫的氯喹敏感性（D6），氯喹/乙胺嘧啶抗性（W2）和多药耐药性（TM91C235）菌株的体外抗疟活性。我们已经开发出一种有效的自动化合成策略，用于大环内酯支架的尿素/硫脲库的快速合成。使用溶液相策略合成化合物，总收率为50–80％。大多数合成的化合物具有抑制作用。前三种化合物对所有三种菌株的效力比阿奇霉素高30-65倍，阿奇霉素具有抗疟疾活性。

  DOI：

  10.1016/j.bmc.2011.01.030
• 作为产物：
  描述：

  5-苯基噻吩-2-羧酸 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 5-苯基-2-噻吩基异氰酸酯
  参考文献：
  名称：

  Axton, Christopher A.; Billingham, Michael E. J.; Bishop, Paul M., Journal of the Chemical Society. Perkin transactions I, 1992, # 17, p. 2203 - 2214

  摘要：

  DOI：

文献信息

• Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
  申请人：Souers J. Andrew

  公开号：US20050137243A1

  公开（公告）日：2005-06-23

  The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

  本发明涉及通过黑色素浓缩激素受体对黑色素浓缩激素（MCH）效应的拮抗，该拮抗对预防或治疗进食障碍、体重增加、肥胖、生殖和性行为异常、甲状腺激素分泌、利尿和水/电解质平衡、感觉处理、记忆、睡眠、唤醒、焦虑、抑郁、癫痫、神经退行性疾病和精神疾病有用。
• [EN] CYCLIC QUATERNARY AMINO DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS<br/>[FR] DERIVES AMINO QUATERNAIRES CYCLIQUES UTILISES COMME RECEPTEURS DE CHIMIOKINE
  申请人：CELLTECH R&D LTD

  公开号：WO2004094381A1

  公开（公告）日：2004-11-04

  Compounds of formula (1) wherein,m,n,R1,R2,Ra,ALK3, E and Y are as defined in the claims, being potent and selective inhibitors of chemokine binding to the CXCR3 receptor, are accordingly of use in the treatment and/or prevention of conditions involving inappropriate T-cell trafficking, including inflammatory, autoimmune and immurforegulatory disorders such as rheumatoid arthritis.

  式（1）中的化合物，其中m，n，R1，R2，Ra，ALK3，E和Y的定义如权利要求中所述，是对CXCR3受体的趋化因子结合具有强效和选择性的抑制剂，因此可用于治疗和/或预防涉及不当T细胞迁移的疾病，包括炎症性、自身免疫和免疫调节性疾病，如类风湿性关节炎。
• Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases
  申请人：Watson John Robert

  公开号：US20050113414A1

  公开（公告）日：2005-05-26

  Cyclic amino derivatives of formula (1) are described: (1) wherein: m and n, which may be the same or different, is each zero or the integer 1 or 2; Alk 3 is a covalent bond or a straight or branched C 1-6 alkylene chain; R 1 and R 2 , which may be the same or different, is each a hydrogen atom or a straight or branched C 1-6 alkyl group; D is an optionally substituted aromatic or heteroaromatic group; E is an optionally substituted C 7-10 cycloalkyl, C 7-10 cycloalkenyl or C 7-10 polycycloaliphatic group; and the salts, solvates, hydrates, tautomers or N-oxides thereof. The compounds are potent and selective modulators of the interaction between CXCR3 and its chemokine ligands and are thus of use in medicine, for example in the prevention or treatment of conditions involving inappropriate T-cell trafficking such as certain inflammatory, autoimmune and immunoregulatory disorders as described hereinafter.

  描述了公式（1）的环状氨衍生物：（1）其中：m和n，可以相同或不同，均为零或整数1或2; Alk3是共价键或直链或支链C1-6烷基链; R1和R2，可以相同或不同，均为氢原子或直链或支链C1-6烷基基团; D是可选的取代芳香族或杂环芳香族基团; E是可选的取代C7-10环烷基，C7-10环烯基或C7-10多环脂肪族基团;以及其盐，溶剂化物，水合物，互变异构体或N-氧化物。这些化合物是CXCR3与其趋化因子配体之间相互作用的强效和选择性调节剂，因此在医学上有用，例如在预防或治疗涉及不适当T细胞转移的疾病中，如下所述的某些炎症，自身免疫和免疫调节性疾病。
• Cyclic quaternary amino derivatives as modulators of chemokine receptors
  申请人：Watson John Robert

  公开号：US20070197589A1

  公开（公告）日：2007-08-23

  Compounds of formula (1) wherein, m, n, R 1 , R 2 , R a , ALK 3 , E and Y are as defined in the claims, being potent and selective inhibitors of chemokine binding to the CXCR3 receptor, are accordingly of use in the treatment and/or prevention of conditions involving inappropriate T-cell trafficking, including inflammatory, autoimmune and immurforegulatory disorders such as rheumatoid arthritis.

  式（1）的化合物中，m，n，R1，R2，Ra，ALK3，E和Y如权利要求中所定义，是对CXCR3受体的趋化因子结合的有效和选择性抑制剂，因此可用于治疗和/或预防涉及不适当T细胞移行的疾病，包括炎症，自身免疫和免疫调节性疾病，如类风湿性关节炎。
• Identification and structure–activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists
  作者：Daniel R. Allen、Amanda Bolt、Gayle A. Chapman、Roland L. Knight、Johannes W.G. Meissner、David A. Owen、Robert J. Watson

  DOI：10.1016/j.bmcl.2006.10.088

  日期：2007.2

  The synthesis and biological evaluation of a series of 1-aryl-3-piperidin-4-yl-urea derivatives as small-molecule CXCR3 antagonists is described. SAR studies resulted in significant improvement of potency and physicochernical properties and established the key pharmacophore of the series, and led to the identification of 9t, which exhibits an IC50 of 16 nM in the GTP gamma S-35 functional assay. (c) 2006 Elsevier Ltd. All rights reserved.